New antirheumatic substance based on phenolic glycoside structure methyl (4-О-Β-glucopyranosyloxy)-benzoic acid; Jurnal Teknologi; Vol. 78, iss. 6-8

Detalhes bibliográficos
Parent link:Jurnal Teknologi.— , 1977-
Vol. 78, iss. 6-8.— 2016.— [P. 79-82]
Autor Corporativo: Национальный исследовательский Томский политехнический университет Институт физики высоких технологий Лаборатория № 1
Outros Autores: Nemtsev A. O. Aleksey Olegovich, Smirnov I. V. Ivan Vladimirovich, Murashko T. O. Tatjyana Olegovna, Ivanov A. A. Aleksey Alekseevich, Bondarev A. A. Aleksandr Aleksandrovich, Udut V. V. Vladimir Vasiljevich
Resumo:Title screen
Rheumatoid arthritis (RA) is a chronic inflammatory multifactorial disorder affecting approximately 1% of population, with over 3000000 new cases annually. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs (NSAID). Patients with rheumatoid arthritis are vulnerable to NSAID-associated gastrointestinal complications. Based on these findings we developed a new NSAID agent based on phenolic glycoside structure methyl (4-О-B-glucopyranosyloxy)-benzoic acid. In this study we evaluated the methyl (4-О-B-glucopyranosyloxy)-benzoic acid therapeutic effect in adjuvant-induced rat arthritis compared to etoricoxib effect. According to the results, methyl (4-О-B-glucopyranosyloxy)-benzoic acid activity was superior to etoricoxib, paw volume returned to the initial value 2 days early, than it did in etoricoxib group. Therefore, methyl (4-О-B-glucopyranosyloxy)-benzoic acid might contest to the modern antirheumatic drug etoricoxib.
Режим доступа: по договору с организацией-держателем ресурса
Idioma:inglês
Publicado em: 2016
Assuntos:
Acesso em linha:http://dx.doi.org/10.11113/jt.v78.9058
Formato: Recurso Electrónico Capítulo de Livro
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=651048
Descrição
Resumo:Title screen
Rheumatoid arthritis (RA) is a chronic inflammatory multifactorial disorder affecting approximately 1% of population, with over 3000000 new cases annually. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs (NSAID). Patients with rheumatoid arthritis are vulnerable to NSAID-associated gastrointestinal complications. Based on these findings we developed a new NSAID agent based on phenolic glycoside structure methyl (4-О-B-glucopyranosyloxy)-benzoic acid. In this study we evaluated the methyl (4-О-B-glucopyranosyloxy)-benzoic acid therapeutic effect in adjuvant-induced rat arthritis compared to etoricoxib effect. According to the results, methyl (4-О-B-glucopyranosyloxy)-benzoic acid activity was superior to etoricoxib, paw volume returned to the initial value 2 days early, than it did in etoricoxib group. Therefore, methyl (4-О-B-glucopyranosyloxy)-benzoic acid might contest to the modern antirheumatic drug etoricoxib.
Режим доступа: по договору с организацией-держателем ресурса
DOI:10.11113/jt.v78.9058